
Mega Doctor News
by Focused Ultrasound Foundation
Newswise — Theraclion has announced that the US Food and Drug Administration (FDA) has granted De Novo authorization for its Sonovein device to treat superficial venous reflux in great saphenous veins (GSV), the main cause of varicose veins. This is the first noninvasive focused ultrasound platform to treat varicose veins, which affect approximately one third of adults.
The FDA’s ruling was based on results from a pivotal clinical trial, called VEINRESET (NCT05926830), which enrolled 70 participants across four sites in the US and Europe. The study met its primary endpoint with a 96.8% GSV occlusion rate after one year. No serious or unanticipated adverse events were reported, and only one mild adverse event was observed.
In anticipation for this milestone, the company has been preparing to launch a US subsidiary, Sonovein, Inc., and has established a dedicated Category III CPT code as an initial step toward insurance coverage.
According to Theraclion’s press release, the company plans to establish reference treatment centers and focus on physician training, clinical onboarding, and technical and service support.
“This authorization marks the culmination of years of clinical and regulatory work and opens a defining new chapter for Theraclion,” said Martin Deterre, PhD, chief executive officer of Theraclion. “Sonovein enables entirely noninvasive vein treatment, without incisions or catheters. We are proud to bring this fundamental advance to US patients and physicians. I thank our teams, clinical investigators, partners, and shareholders, whose dedication and belief in our vision helped make this achievement possible. We also thank the FDA for its constructive engagement throughout the review process.”
See Theraclion’s Press Release














